Intermedin Ameliorates Atherosclerosis by Increasing Cholesterol Efflux Through the cAMP-PKA Pathway in Macrophage RAW264.7 Cell Line

Hang Liao
Shixi Wan
Xin Zhang
Di Shi
Xiaojiang Zhu
Xiaoping Chen

Background: The aim of this study was to explore the role of intermedin and its mechanism in cholesterol efflux of macrophage THP-1 and RAW264.7 cell lines in atherosclerosis (AS).

Material/Methods: ApoE−/− mice were fed with a high-fat diet, and the concentrations of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. The lipidoses of the aortic sinus were analyzed by hematoxylin and eosin staining, and the cAMP level was detected by enzyme-linked immunosorbent assay (ELISA). The expressions of ATP-binding cassette transporter (ABCA1) were tested by real-time PCR and Western blot analysis.

Results: IMD decreased serum TC and LDL-C, and increased serum HDL-C level in apoE−/− mice and attenuated AS plaque areas. In vitro, IMD increased intracellular cAMP concentration in a dose-dependent manner in THP-1 and RAW264.7 cell lines, which enhanced the expression of ABCA1 and increased cholesterol efflux rate. However, this effect was inhibited by PKAI in the RAW 264.7 cell line but not in the THP-1 cell line.

Conclusions: IMD can ameliorate the development of AS in ApoE−/− mice and regulate cholesterol balance in the RAW264.7 cell line through the cAMP-PKA pathway.

MeSH Keywords: Atherosclerosis • ATP Binding Cassette Transporter 1 • Cyclic AMP-Dependent Protein Kinase Rialpha Subunit • Cyclic AMP-Dependent Protein Kinases

Corresponding Author: Xiaoping Chen, e-mail: xiaopingchen21@163.com
Source of support: This study was supported by the Natural Science Foundation of China (Grant No. 81370374)
Background

Atherosclerosis (AS) is one of the leading causes of death among cardiovascular diseases, which is attributed to the uptake of oxidized low-density lipoprotein (ox-LDL) by macrophage and foam cell formation that are accumulated by intracellular cholesterol in the artery wall [1]. Macrophage-derived foam cell formation is considered to be a hallmark in this process [2]. High-density lipoprotein (HDL) is believed to play a protective role in transporting cholesterol to the liver from the peripheral tissues, and an elevated level of HDL is associated with a lower level of cholesterol in foam cells [3]. ATP-binding cassette transporter A1 (ABCA1) is a first and rate-limiting step of this reverse cholesterol transport (RCT) process, which is also a key mediator in regulating cellular cholesterol homeostasis expressed on the fat-laden macrophage surface [4,5]. Mutations of ABCA1 genes are known to have a severe deficiency of HDL, thus resulting in AS [6]. As the cAMP-inducible apolipoprotein receptor, ABCA1 promotes lipids secretion from the macrophages, and is also phosphorylated by protein kinase A (PKA) or a PKA-like kinase in vivo [7,8]. Hu et al. reported that PKA is involved in the ABCA1-mediated cholesterol efflux [9]. Nevertheless, whether the cAMP-PKA-ABCA1 pathway is feasible in the setting of increasing cholesterol efflux is not fully understood.

Intermedin (IMD), an intrinsic active polypeptide (also known as adrenomedullin-2), is a newly identified member of the calcitonin gene-related peptide (CGRP) superfamily that was found by Roh et al. [10]. IMD is widely distributed in the peripheral and central nervous system of humans and mice and is known for its antioxidant and antiinflammatory properties. Other biological effects associated with IMD include facilitating vessel dilation, inhibiting vessel calcification, and enhancing myocardial contraction [11]. Recent studies have shown that exogenous IMD treatment plays a protective role in AS by ameliorating AS plaque in ApoE−/− mice by inhibiting SR-A and CD36 in macrophages and decreasing foam cell formation, indicating that IMD functions in regulating lipid metabolism and delaying AS development [12,13].

However, the potential molecular mechanism of the anti-AS function of IMD remains unclear. In the present study, we investigated the underlying mechanism of the effect on ABCA1 expression and ABCA1-mediated cholesterol efflux by IMD in the RAW264.7 cell line, which are mouse macrophage-derived foam cells. We demonstrate that IMD significantly increased ABCA1 expression through the cAMP-PKA signaling and decreased cholesterol retention in the RAW264.7 cell line. Here, we provide a novel mechanism of the cAMP/PKA-mediated cholesterol efflux by IMD administration and explain its role in anti-AS function.

Material and Methods

Animals

Twenty-four ApoE−/− mice (male, 8 weeks old, 18–20 g) were purchased from the Institute of Model Animals in Nanjing University and housed in a pathogen-free animal facility at West China Hospital of Sichuan University. Mice were fed with a high-fat diet (15.8% fat and 1% cholesterol) for 10 weeks to produce AS and then were equally divided into 3 groups: normal saline (N=8), 100 ng/kg/h of IMD (N=8), and 500 ng/kg/h of IMD (N=8). All mice were implanted with IMD for 6 weeks by an osmotic pump under local anesthesia. All animal experimental protocols were approved by the Institutional Animal Care and Use Committee at West China Hospital of Sichuan University.

Cell culture and transduction

The human macrophage cell line THP-1 and the mouse macrophage cell line RAW264.7 were obtained from the American Type Culture Collection. THP-1 was cultured in 1640 medium with 10% fetal bovine serum (FBS) (Gibco), supplemented with 1% penicillin-streptomycin (Hyclone, USA) in a humidified incubator containing 5% CO₂, at 37°C. We seeded and induced 2.5×10⁵ cells using 50 ng/ml of phorbol myristate acetate (PMA). Macrophage THP-1 was successfully induced by observing the cells attached to the bottom. RAW264.7 was cultured in Dulbecco modified Eagle’s medium (DMEM, Gibco, USA) in 10% FBS (Gibco) and supplemented with 1% penicillin-streptomycin (Hyclone) in a humidified incubator containing 5% CO₂, at 37°C.

Reagents

IMD was purchased from Phoenix BioTECH (Beijing, China). PMA, 3H-cholesterol, and ApoA-I were purchased from Sigma. The cAMP parameter assay kit was obtained from R&D Systems (Shanghai, China). Trizol reagent was obtained from Invitrogen, USA. The antibodies against ABCA1 (ab18180) and β-actin (ab8227) were purchased from Abcam (Shanghai, China). HE staining reagent was bought from Beyotime Biotechnology (Haimen, China).

Real-time polymerase chain reaction (RT-PCR)

Total RNA was isolated from THP-1 and RAW264.7 cells. We reverse transcribed 1 µg of total RNA using iScript™ reverse transcription (Bio-Rad, USA), as recommended by the manufacturers. Expression of mABCA1 and hABCA1 and the internal control m-β-Actin and h-β-Actin mRNA levels were analyzed using quantitative real-time RT-PCR on an iCycler thermocycler (Bio-Rad). TaqMan assays were obtained from Applied Biosystems.
The relative quantities of mABCA1 and hABCA1 were calculated using iCycler IQ Real-Time Detection System software (version 3.0a; Bio-Rad, USA) through the comparative threshold method (ΔΔCt), using m-β-Actin and h-β-Actin as endogenous controls. The sequences for mABCA1 were: forward: 5′-GGGTCTGAACTGCCCTACT-3′, reverse: 5′-TACTCCCTGTAGCCACCTTC-3′; hABCA1 were: forward: 5′-GGCTGCTAGTGTCATTCTG-3′; reverse: 5′-CCACCGTGATCTGA-3′; m-β-Actin, forward: 5′-CTAACGCCAACCGTGAAG-3′; and reverse: 5′-GCCAGGGCGTACCCGACA-3′; h-β-Actin, forward: 5′-CCAAACCGGAAGAGATGA-3′ and reverse: 5′-CCAGGGCGTACA GGGATAG-3′.

**Lipid profile measurement**

A blood sample was extracted from the eyeball after 12-h fasting. Serum was obtained by centrifugation at 4000 rpm for 15 min at 4°C and preserved at –80°C before analysis. Serum lipoproteins levels were measured enzymatically using an automatic biochemistry analyzer (Hitachi7600, Japan).

**HE staining**

The tissue sections were deparaffinized in xylene, rehydrated with a graded series of ethanol, and then endogenous peroxidase activity was blocked by a 5-min incubation in 3% hydrogen peroxide in methanol. After two 5-min washes with phosphate-buffered saline, an avidin-biotin complex and immunoperoxidase were applied. Slides were then washed in isopropanol for 10 min, rinsed in tap water, counterstained with hematoxylin and mounted in a glycerol/gelatin solution. Images of cells were then captured using an Olympus light microscope (Tokyo, Japan).

**Statistical analysis**

Data are expressed as mean ±SD, and statistical analysis was performed via a t test or one-way analysis of variance. A p value less than 0.05 was considered statistically significant.

**Results**

**IMD regulates lipid metabolism and attenuates AS in ApoE–/– mice**

To determine the effects of IMD on the lipid metabolism in AS in vivo, ApoE–/– mice were fed a high-fat diet for 10 weeks to develop AS. The mice were divided into groups based on the IMD dose, then we measured the levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and HDL-C. We observed that TC decreased dramatically after high IMD stimulation (9.47±1.20 vs. 11.12±1.42, p<0.05) (Table 1). High-dose IMD decreased the LDL-C level significantly more than in the low-dose group, while HDL-C increased both in the low-dose and high-dose stimulation. No difference was observed in the TG group (p>0.05). Next, each of the AS plaques were measured by hematoxylin and eosin staining (Figure 1A–1C). We found that the AS plaque was prominently reduced by 37% in the 500 ng/kg/h group and reduced by 18.5% in the 100 ng/kg/h group (Figure 1D). Therefore, IMD-mediated lipid metabolism regulation may help relieve the process of atherosclerosis in ApoE–/– mice.
Table 1. Effects of IMD on lipid metabolism.

| Item                  | Vehicle (n=8) | IMD 100 ng/kg/h (n=8) | IMD 500 ng/kg/h (n=8) | P value |
|-----------------------|--------------|----------------------|----------------------|---------|
| Weight (g, 8 weeks)   | 18.83±1.04   | 18.25±0.81           | 18.64±0.71           | 0.983   |
| Weight (g, 25 weeks)  | 29.59±2.88   | 29.16±2.47           | 28.29±2.05*          | 0.063   |
| TG (mmol/L)           | 1.55±0.13    | 1.53±0.12            | 1.50±0.16            | 0.75    |
| TC (mmol/L)           | 13.71±1.22   | 11.12±1.42*          | 9.47±1.20**          | 0.001   |
| LDL-C (mmol/L)        | 5.13±0.86    | 4.59±0.43            | 4.19±0.63*           | 0.034   |
| HDL-C (mmol/L)        | 0.80±0.08    | 0.96±0.11*           | 1.02±0.16*           | 0.002   |

Vehicle – using saline as the control group. IMD 100 ng/kg/h – IMD low concentration group; IMD 500 ng/kg/h – IMD low concentration group. Data are presented as mean ±SD. * p<0.05, as compared with Vehicle; # p<0.05, as compared with IMD low concentration group.

Figure 1. IMD attenuates atherosclerosis. Atherosclerotic plaque was reduced significantly in the 100 ng/kg/h group and the 500 ng/kg/h group. (A) Vehicle control group. (B) IMD 100 ng/kg/h group. (C) IMD 500 ng/kg/h group. (D) Analysis of atherosclerotic plaque between the 3 groups. * Compared with control group (P<0.05) # compared with IMD 100 ng/kg/h group (P<0.05).
IMD facilitates cholesterol efflux in macrophages

IMD enhanced the expression of HDL in ApoE−/− mice, which is related to a lower level of cholesterol in the foam cells. Therefore, we explored how the cholesterol efflux in IMD influences cholesterol balance in macrophages. Macrophage THP-1 was transferred successfully from its floating monocyte type by 50-ng/ml PMA inducement. The morphology of the macrophage THP-1 was observed under a microscope at 10× and 100× and we confirmed the transformation in 48 h. Counts per minute (CPM) was used to measure medium- and cell-associated [3H] cholesterol. (A) 0 h 10×. (B) 24 h 10×. (C) 48 h 10×. (D) 48 h 100×. (E) CPM in THP-1. (F) CPM in RAW264.7. (* P<0.05).

**Figure 2.** Intermedin facilitates cholesterol efflux in macrophages. Macrophage THP-1 was induced by 50 ng/ml PMA. The morphology of the macrophage THP-1 was observed at 10× and 100× under a microscope and confirmed the transformation in 48 h. Counts per minute (CPM) was used to measure medium- and cell-associated [3H] cholesterol. (A) 0 h 10×. (B) 24 h 10×. (C) 48 h 10×. (D) 48 h 100×. (E) CPM in THP-1. (F) CPM in RAW264.7. (* P<0.05).
p<0.001), while no simultaneous rise in the CPM of cholesterol (p>0.05) was detected with increased IMD concentration. As for the RAW264.7, CPM was elevated as well, and a proportional rise of the concentration of IMD was observed, and was 2-fold higher in the 100 nM group (1.54±0.17 vs. 0.46±0.11, p<0.001). These results suggest that IMD is required for the promotion of the efflux of cholesterol from macrophages and exerts an anti-AS function.

Figure 3. Intermedin promotes the expression of ABCA1. Cell mRNA and protein of ABCA1 was extracted and measured by PCR and Western blot. (A) mRNA of ABCA1 in THP1. (B) mRNA of ABCA1 in RAW264.7. (C) Protein of ABCA1 in THP1 (left figure in the C panel is the grey-image scanning). (D) Protein of ABCA1 in RAW264.7 (left figure in panel D is the grey-image scanning) (* P<0.05).
IMD promotes the expression of ABCA1

ABCA1 is a critical mediator in the RCT process. To determine if IMD regulates cholesterol homeostasis through ABCA1, the expression of ABCA1 was detected. The mRNA of ABCA1 notably increased after IMD treatment for 24 h in THP-1 and RAW264.7 cells, which is 2 times higher in THP-1 than that in the control group and 3 times higher than in RAW264.7 cells (Figure 3A, 3B). Expression of ABCA1 protein was also found to be promoted, along with the elevated IMD infusion (Figure 3C, 3D). These findings show that IMD exerts a positive effect on ABCA1 expression, which further influenced cholesterol efflux in macrophages.

IMD enhances cAMP level in the macrophage

Since IMD affected the promotion of ABCA1, we investigated whether IMD is essential in the cAMP-PKA-ABCA1 signal pathway. ELISA was used to measure the cAMP level in transferred THP-1 and RAW264.7 after 24 h by IMD infusion. There was no significant difference in 25 nM administration of IMD for 24 h; however, when the high dose of IMD was given, cAMP rose by 38.7% in the 50-nM group and was 3 times higher in the 100-nM group compared to the control group (Figure 4A). The level of cAMP in RAW264.7 followed a similar trend as with THP-1, while cAMP was enhanced by 55.8% more than in the control group and was 100 nM higher with IMD (Figure 4B). These results show that IMD can increase the cAMP level in both of these cell lines in a dose-dependent manner, and the effect of this phenomenon was more obvious in THP-1.

PKAI inhibits ABCA1 and cholesterol efflux

To determine whether the effects of IMD on the cholesterol efflux were mediated by the cAMP-PKA-ABCA1 pathway, PKAI, a potent inhibitor of PKA, was utilized. The expression of ABCA1 in THP-1 did not show a significant decrease with PKAI treatment. However, an interesting finding was noted with respect to RAW264.7, wherein a decreasing trend was also noted in the ABCA1 expression and cholesterol efflux (Figures 5, 6). These findings show that IMD exerts a positive effect on cholesterol efflux from the macrophages through the cAMP-PKA-ABCA1 mechanism in RAW264.7 but not in THP-1.

Discussion

The present study demonstrates that intravenous IMD infusion ameliorates AS plaque formation, decreases the level of TC and LDL, and increases HDL in vivo. Further, exogenous IMD administration enhances the cholesterol efflux in THP-1 and RAW264.7. Additionally, this study described a novel mechanism illustrating the effects of IMD on regulating cholesterol homeostasis via the cAMP-PKA-ABCA1 signaling pathway in RAW264.7, suggesting ABCA1 is required for the IMD-mediated cholesterol efflux.

Cholesterol efflux is a critical part of RCT to remove the over-loaded cholesterol from the macrophages in the subintima of the vessel wall to HDL or apolipoprotein (apo) A-I by a variety of mechanisms, including a pathway dependent on a cell membrane protein called ABCA1. ABCA1 is a member in a large family of ABC transporters, which is characterized by two ATP binding domains and two 6-helix transmembrane domains [14]. Mutation in ABCA1 causes a severe shortage of HDL, resulting in a prevalent AS [15–17]. In the present study, we showed that ABCA1 expression in macrophages is highly regulated on both transcriptional and post-transcriptional levels by IMD treatment in THP-1 and RAW264.7 [18]. The elevated ABCA1...
might explain the reduced serum TC, LDL-C level, and attenuated AS plaque area, and elevated serum HDL-C in ApoE−/− mice that promoted the cholesterol efflux rate from THP-1 and RAW264.7 macrophage-derived foam cells.

cAMP is a known second messenger, acting both at the mRNA and protein level, up-regulating ABCA1 expression [19,20]. The identification of a cAMP-responsive element is considered to be important for the induction of ABCA1 gene expression. In the present study, an elevated level of cAMP in both human and mouse macrophage cell lines was observed, with promotion in THP-1 ABCA1 expression observed twice, and 3 times in RAW264.7 by IMD treatment. The present study results are in line with results reported by Hu et al., who concluded that

Figure 5. PKAI inhibits ABCA1 expression. Cell mRNA and protein of ABCA1 was extracted and measured by PCR and Western blot after being treated by PKAI. (A) mRNA of ABCA1 in THP1. (B) mRNA of ABCA1 in RAW264.7. (C) protein of ABCA1 in THP1(right figure in the C panel is the grey image scanning). (D) Protein of ABCA1 in RAW264.7 (right figure in panel D is the grey-image scanning) (* P<0.05).
Eicosapentaenoic acid (EPA) inhibit the ABCA1 protein and cholesterol efflux through cAMP-PKA in THP-1 [9]. Apart from the induction of ABCA1, cAMP is also an activator of PKA, which is reported to be involved in stimulating the efflux of cholesterol. Blocking the effect of PKA has an inhibitory effect on the phosphorylation of ABCA1 and cholesterol efflux [21, 22]. In the present study, we showed that PKAI obviously decreased ABCA1 expression and suppressed cholesterol efflux by IMD in RAW264.7 but not in THP-1, indicating that IMD regulates ABCA1-mediated cholesterol efflux through PKA induction in the mouse macrophages but not in the human macrophages. Our present results agree with those of several other studies, but conflict with the results reported by Hu et al., who found that ABCA1 was modulated by cAMP-PKA in THP-1, a human macrophage cell line [23]. However, Bortnick et al. earlier put forward a concept that the response to cAMP was different in human and mouse ABCA1 genes, and only the latter showed a substantial induction in macrophages by cAMP treatment [24]. It has been reported that the liver X receptors (LXR)/retinoid X receptor (RXR) pathways transcriptionally regulated ABCA1 as well, which may provide a new insight that the RXR pathway that may be involved in human macrophage cells because THP-1 lacks the cAMP response element binding protein (CREBP). Further studies in this area are needed.

IMD is a novel vasoactive peptide of the CGRP superfamily, which inhibits vascular calcification and impairs AS lesions in ApoE/−/− mice. In recent studies, IMD was reported to ameliorate foam-cell formation via suppressing scavenger receptor A (SR-A), induced mostly by acetylated LDL (acLDL) and CD36 mainly derived from oxidized LDL (oxLDL) with IMD infusion, which both contributed to foam-cell formation [13, 25]. Our study shows a novel mechanism by which IMD may be a potential therapeutic candidate for treating AS through promoting the cholesterol efflux. IMD is also a potent vasodilator by increasing cAMP production, and continuous IMD treatment decreases blood pressure and improves hemodynamic function in spontaneously hypertensive rats via the cAMP-PKA pathway [10, 11, 26, 27].

**Conclusions**

In conclusion, we demonstrated a new mechanism by which IMD ameliorates the formation of foam cells and can be used to treat AS by promoting cholesterol efflux via (at least partly) a cAMP-PKA pathway-dependent mechanism in RAW264.7 and THP-1 cell lines. More specific functions and mechanisms of IMD in atherogenesis remain to be explored.

**Acknowledgement**

The authors would like to acknowledge the Key Laboratory and Endocrinology Laboratory at West China Hospital of Sichuan University for supporting this study.

**Conflict of interests**

None.
References:

1. Libby P. Atherosclerosis: Disease biology affecting the coronary vasculature. Am J Cardiol, 2006; 98: 3Q–9Q

2. Yu KH, Fu YC, Zhang DW et al: Foam cells in atherosclerosis. Clin Chim Acta, 2013; 424: 245–52

3. Chiesa G, Monteggia E, Marchesi M et al: Recombinant apolipoprotein A-I(Milan) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res, 2002; 90: 974–80

4. Aiello RI, Brees D, Francone OL: ABCA1-deficient mice: Insight into the role of monocyte lipid efflux in HDL formation and inflammation. Arterioscler Thromb Vasc Biol, 2003; 23: 972–80

5. Joyce C, Freeman L, Brewer HB Jr., Santamarina-Fojo S: Study of ABCA1 function in transgenic mice. Arterioscler Thromb Vasc Biol, 2003; 23: 965–71

6. Schumacher T, Benndorf RA: ABC transport proteins in cardiovascular disease—a brief summary. Molecules, 2017; 22(4): pii: E589

7. Cui X, Chopp M, Zhang Z et al: ABCA1/ApoE/HDL pathway mediates GW3965-induced neurorestoration after stroke. Stroke, 2017; 48: 459–67

8. Oram JF, Lawn RM, Garvin MR, Wade DP: ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem, 2000; 275: 34508–11

9. Hu YW, Ma X, Li XX et al: Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cAMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis, 2009; 204: e13–43

10. Hu YW, Ma X, Li XX et al: Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cAMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis, 2009; 204: e13–43

11. Roh J, Chang CL, Bhalla A et al: Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem, 2004; 279: 7264–74

12. Takei Y, Inoue K, Ogoshi M et al: Identification of novel adrenomedullin in teleosts as well as in mammals: A comparison with other vertebrate adrenomedullin. Peptides, 2004; 25(10): 1643–56

13. Zhang X, Gu L, Chen X et al: Intermedin ameliorates atherosclerosis in ApoE null mice by modifying lipid profiles. Peptides, 2012; 37: 189–93

14. Luciani MF, Denizot F, Savary S et al: Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics, 1994; 21: 150–59

15. Züchner S, Sperfeld AD, Senderek J et al: A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease. Brain, 2003; 126: 920–27

16. Bertolini S, Pisciotto L, Seri M et al: A point mutation in ABC1 gene in a patient with severe premature coronary heart disease and mild clinical phenotype of Tangier disease. Atherosclerosis, 2001; 154: 599–605

17. Oram JF, Vaughan AM: ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr Opin Lipidol, 2000; 11: 253–60

18. Yokoyama S: ABCA1 and biogenesis of HDL. J Atheroscler Thromb, 2006; 13: 1–15

19. Tang CK, Tang GH, Yi GH et al: Effect of apolipoprotein A-I on ATP binding cassette transporter A1 degradation and cholesterol efflux in THP-1 macrophage-derived foam cells. Acta Biochim Biophys Sin (Shanghai), 2004; 36(3): 218–26

20. Haidar B, Denis M, Krimbou L et al: cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts. J Lipid Res, 2002; 43(12): 2087–94

21. Lin G, Bornfeldt KE: Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux. Biochem Biophys Res Commun, 2002; 290(2): 663–69

22. Osheroff JE, Visconti PE, Valenzuela JP et al: Regulation of human sperm capacitation by a cholesterol efflux-stimulated signal transduction pathway leading to protein kinase A-mediated up-regulation of protein tyrosine phosphorylation. Mol Hum Reprod, 1999; 5(11): 1017–26

23. Le Goff W, Zheng P, Brubaker G, Smith JD: Identification of the cAMP-responsive enhancer of the murine ABCA1 gene: Requirement for CREB1 and STAT3/4 elements. Arterioscler Thromb Vasc Biol, 2006; 26(3): 527–33

24. Bortnick AE, Rothblat GH, Stoudt G et al: The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J Biol Chem, 2000; 275(37): 28634–40

25. Wang Y, Yang K, Chen X et al: Intermedin inhibits uptake of oxidized LDL via CD36 pathway in RAW264.7 cells. Pharmacol, 2014; 69(6): 473–76

26. Takei Y, Hyodo S, Katafuchi T, Minamino N: Novel fish-derived adrenomedullin in mammals: Structure and possible function. Peptides, 2004; 25(10): 1643–56

27. Chang CL, Roh J, Hsu SY: Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: A comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides, 2004; 25: 1633–42